Trial · NCT02506153
Results by group276
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 276
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | FDA Approved Regimen (SOC) | 76 | 95% Confidence Interval 73 to 80 | percentage of participants | |
| Overall Survival (OS) | MK-3475 (Pembrolizumab) | 82 | 95% Confidence Interval 78 to 84 | percentage of participants | |
| Relapse-free Survival (RFS) | FDA Approved Regimen (SOC) | 49 | 95% Confidence Interval 45 to 53 | percentage of participants | |
| Relapse-free Survival (RFS) | MK-3475 (Pembrolizumab) | 58 | 95% Confidence Interval 54 to 62 | percentage of participants | |
| Overall Survival (OS) in Participants Who Are PD-L1 Positive | FDA Approved Regimen (SOC) | 79 | 95% Confidence Interval 74 to 82 | percentage of participants | |
| Overall Survival (OS) in Participants Who Are PD-L1 Positive | MK-3475 (Pembrolizumab) | 83 | 95% Confidence Interval 80 to 86 | percentage of participants | |
| Relapse-free Survival (RFS) in Participants Who Are PD-L1 Positive | FDA Approved Regimen (SOC) | 51 | 95% Confidence Interval 46 to 55 | percentage of participants | |
| Relapse-free Survival (RFS) in Participants Who Are PD-L1 Positive | MK-3475 (Pembrolizumab) | 60 | 95% Confidence Interval 56 to 64 | percentage of participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | FDA Approved Regimen | Abdominal pain | 6 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | MK-3475 (Pembrolizumab) | Abdominal pain | 2 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | FDA Approved Regimen | Acidosis | 1 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | MK-3475 (Pembrolizumab) | Acidosis | 2 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | FDA Approved Regimen | Acute kidney injury | 2 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | MK-3475 (Pembrolizumab) | Acute kidney injury | 2 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | FDA Approved Regimen | Adrenal insufficiency | 9 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | MK-3475 (Pembrolizumab) | Adrenal insufficiency | 4 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | FDA Approved Regimen | Alanine aminotransferase increased | 44 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | MK-3475 (Pembrolizumab) | Alanine aminotransferase increased | 19 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | FDA Approved Regimen | Alkaline phosphatase increased | 3 | Participants | |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | MK-3475 (Pembrolizumab) | Alkaline phosphatase increased | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02506153/results